We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ENHANZE

News List

Collaboration to develop ultra-long acting medicines for HIV europeanpharmaceuticalreview
June 23, 2021
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
Pertuzumab, Trastuzumab Combination with ENHANZE Drug Delivery Meets Primary Endpoint americanpharmaceuticalreview
September 17, 2019
Halozyme announced the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
Argenx to leverage Halozyme’s subcutaneous drug delivery technology pharmaceutical-technology
February 19, 2019
Dutch biotechnology company Argenx has signed a global collaboration and licence agreement to leverage US-based Halozyme Therapeutics’ drug delivery technology ENHANZE....
Halozyme licenses $25M drug delivery technology to Roche biospectrumasia
November 26, 2018
Halozyme has out-licensed its ENHANZE drug delivery technology to Roche for the exclusive development of a new undisclosed drug target with an option to add two more within four years.
Bristol-Myers Squibb collaborates with ENHANZE technology biospectrumasia
September 18, 2017
Under the agreement, Halozyme to receive $105 million upfront payment, plus future milestones and royalties